Skip to main content
BRAF Status in Personalizing Treatment Approaches for Pediatric Gliomas.
Impact of Two Measures of Micrometastatic Disease on Clinical Outcomes in Patients with Newly Diagnosed Ewing Sarcoma: A Report from the Children's Oncology Group.
Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors.
Spinal Myxopapillary Ependymomas Demonstrate a Warburg Phenotype.
Phase I Study of Vorinostat as a Radiation Sensitizer with 131I-Metaiodobenzylguanidine (131I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma.
BET bromodomain inhibition of MYC-amplified medulloblastoma.
Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial.
It takes two to tango: Dual inhibition of PI3K and MAPK in rhabdomyosarcoma.
Generation of tumor antigen-specific T cell lines from pediatric patients with acute lymphoblastic leukemia--implications for immunotherapy.
Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma.